Clinical Trials Browser

Phase 2 × anlotinib × Breast × Clear all

NCT07520760 2026-04-09

MBC-EA

Phase 2 Recruiting

Breast Neoplasms

NCT04877821 2026-04-02

NeoSACT

Phase 2 Completed

Triple Negative Breast Neoplasms

NCT07396454 2026-02-09

Study on the Treatment of HER2-negative Breast Cancer Brain Metastases With Radiotherapy Combined With Anlotinib

Phase 2 Recruiting

HER2-Negative Breast Cancer

NCT07330544 2026-01-09

A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy

Phase 2 Recruiting

Breast Neoplasms

NCT05582499 2025-08-22

FASCINATE-N

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06874933 2025-08-12

Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03)

Phase 2 Recruiting

Breast Neoplasms

NCT06992336 2025-05-28

Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy

Phase 2 Recruiting

Breast Neoplasms

NCT06678230 2024-11-07

Clinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast Cancer

Phase 2 Unknown

Breast Neoplasms

NCT06547476 2024-08-09

Chidamide and PD-1 Inhibitor Plus Anlotinib for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed

Phase 2 Not yet recruiting

Breast Neoplasms

NCT04914390 2024-01-22

NeoATCT

Phase 2 Unknown

Triple Negative Breast Neoplasms

NCT05296577 2023-09-25

Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer

Phase 2 Unknown

Breast Neoplasms

NCT05206656 2022-11-23

Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT05558722 2022-09-28

ACNTBC

Phase 2 Unknown

Breast Neoplasms

NCT05089643 2022-01-10

Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer

Phase 2 Unknown

Triple Negative Breast Neoplasms

NCT05075512 2021-10-12

The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer

Phase 2 Recruiting

Breast Neoplasm Female

NCT04975451 2021-07-27

ADCb (Anlotinib/Docetaxel/Carboplatin) as Neoadjuvant Therapy for Triple-Negative Breast Cancer

Phase 2 Unknown

Breast Neoplasms

NCT04452370 2021-07-21

Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer

Phase 2 Unknown

Triple Negative Breast Neoplasms

NCT04936295 2021-06-23

Fulvestrant Plus Anlotinib in HR(+)/HER2(-) Metastatic Breast Cancer With FGFR Mutation

Phase 2 Unknown

Breast Neoplasms

NCT04624711 2021-05-21

Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer

Phase 2 Unknown

HER2-negative Breast Cancer

NCT04002284 2020-07-29

Anlotinib in Metastatic HER2 Negative Breast Cancer

Phase 2 Completed

Breast Neoplasms